Vyome Holdings, Inc. (HIND)

Vyome Holdings, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Vyome Holdings, Inc. (HIND) is a Biotechnology company based in US with a market capitalization of $14.5M. Revenue declined 96.0% year-over-year and free cash flow was negative at -$3.7M. This page tracks HIND's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 18 employees · IPO Oct 6, 2016

Valuation

Valuation & price

$1.89as of May 17, 2026· -87.9% vs 52w high

P/E ratio

Latest-FY diluted EPS

5.92

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$15.68$8.79$1.89Jul 25Jan 26Jul 26
$1.8952-week range$15.68
Loading valuation history…

Fundamentals

Key fundamentals

$14.5M

Market cap

-96.0%

Revenue growth (YoY)

64.7%

Gross margin

-$3.7M

Free cash flow (USD)

-$5M

Net debt

Net cash position

10380.8%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$786.7K$319.7K

Free cash flow by year

20162025

-$20.7M-$3.7M

Gross margin by year

20212025

61.4%64.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventMay 29, 2026Filing

    Earnings Release

  • Quarterly reportMay 12, 2026Filing

    10-Q Filed

  • 8-K eventApr 29, 2026Filing

    Authorized Shares Decrease

Questions

Frequently asked questions

What is Vyome Holdings, Inc.'s market cap?

Vyome Holdings, Inc. (HIND) has a market capitalization of $14.5M.

What is HIND's P/E ratio?

A meaningful P/E ratio is not available for HIND — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is HIND's price-to-book (P/B) ratio?

HIND trades at 5.92 times book value per share.

Are insiders buying HIND stock?

SEC Form 4 filings show no open-market insider buys at Vyome Holdings, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.